Trending Topic

4 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Welcome to the latest edition of touchREVIEWS in Respiratory & Pulmonary Diseases. As we continually strive to deliver cutting-edge research and insightful commentary, this issue is no exception, featuring a diverse array of articles that illuminate both emerging treatments and evolving practices within the field of respiratory and pulmonary medicine. We begin with a compelling […]

Ivan O. Rosas, ERS 2022: Therapeutic Intervention for Interstitial Lung Disease in Patients with Rheumatoid Arthritis

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Sep 30th 2022

TRAIL1 (ClinicalTrials.gov Identifier: NCT02808871) was a phase 2 randomised, double blind, placebo-controlled trial investigating pirfenidone in rheumatoid arthritis-associated interstitial lung disease (RA-ILD). We were delighted to speak to Professor Ivan O. Rosas (Baylor College of Medicine, Baylor Medicine McNair Campus, Houston, TX, USA) around the prognosis, choice of therapeutic intervention and the rationale for investigating antifibrotic agents in RA-ILD.

The abstract ‘Randomized, Double Blinded, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease.‘ (Abstract number: RCT2886) was presented at ERS 2022, 4–6 September, 2022.

Questions

  1. Could you give us a brief overview of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA)? (0:52)
  2. How does the presence of ILD in RA influence the prognosis and choice of therapeutic intervention? (3:49)
  3. What is the rationale for investigating antifibrotic agents in RA-ILD? (5:27)

Disclosures: Ivan O. Rosas discloses consulting for Genentech/Roche and receiving grant/ research support from Genentech/Roche.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.

Filmed in coverage of the ERS meeting 2022.

For further information, please view the published study article here and the design article here.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup